UnitedHealth Group has long been one of the most powerful players in the American healthcare sector. Developments in recent weeks suggest that this stock could become even more prominent in the coming period. Mega-cap companies like $UNH typically have over 1 billion shares. However, UnitedHealth has only 910 million shares outstanding. Approximately 87% of this is held by institutional investors. This means the remaining free float is less than 100 million.

This represents significant potential. As demand for the stock increases, price movements can be much more rapid and dramatic due to the limited number of shares available. Indeed, last week, the surge in demand, sparked by news that figures like Buffett and Burry had opened positions, caused the stock to rise 14% in a single day. This could indicate a squeeze effect is imminent.

In the last quarter, $UNH was the most frequently purchased stock among hedge funds and superinvestors. While most individual investors have been anxiously sidelined, smart money continues to accumulate the stock. Additionally, we know that members of Congress and insiders have made significant purchases. This year alone, insider purchases have exceeded $55 million. The simultaneous buying of regulators and insiders boosts investor confidence. Such purchases are generally considered a strong indicator of confidence in the company's future.

Today, $UNH trades at a P/E ratio of just 13. This means it's still relatively cheap compared to its earnings. Furthermore, with a 3% dividend yield, it offers an attractive passive income source for long-term investors. The company's dividend payout ratio is 32%, indicating it can allocate a significant portion of its free cash flow to buybacks. The company has been aggressive in its share buyback efforts for years. Free cash flow is expected to reach $25 billion next year. This could result in more than $1 billion in share buybacks per month. This would further reduce the outstanding share supply, accelerating the price increase.

Another factor investors should not overlook is CEO influence. The return of former CEO Stephen Hemsley is considered a positive signal in the market. When Hemsley took office in 2006, $UNH was experiencing a serious crisis, and he quickly revitalized the company, generating over 500% returns for investors. Today, he is said to have demonstrated that same energy, working over 17 hours a day in his office.

1) Company Profile

• Symbol: $UNH

• Market Capitalization: $275.33 billion

• Business Sector: Healthcare, health insurance, pharmacy management, data analytics.

• Stock Exchange: NYSE

• Included in Indices: S&P 500, Dow Jones Industrial Average (DJIA) – its weight in the S&P 500 is approximately 1.1%.

• Headquarters and Founding: Minnetonka, Minnesota, USA – Founded in 1977.

• Founder-led company?: No, management is handled by a professional team.

• What does it do?: UnitedHealthcare provides health insurance services, while Optum operates in data analytics, healthcare services, and pharmacy.

• Is it multinational?: Yes

• Number of Employees: 400,000

• Institutional Ownership: 87% – Large investors like Vanguard, BlackRock, and State Street hold the largest stake.

• Insider Purchases: In May 2025, the CEO, CFO, and board members made substantial stock purchases totaling $55 million+. This demonstrates internal confidence in the company's long-term potential.

2) Revenue Streams (How Does It Make Money?)

The company's operations are divided into four main business segments:

A) UnitedHealthcare: Insurance solutions for individuals and employers (54% revenue)

B) OptumRx: Prescription drug management and pharmacy solutions (24% revenue)

C) OptumHealth: Healthcare (19% revenue)

D) OptumInsight: Data analytics and consulting services (3% revenue)

• Total revenue (2024): $422.82 billion

• 2025 forecast: $448 billion (+11% annual growth)

3) Financial Health

• Gross Margin: 20.8% (Note: The initial profit margin after sales. 15-25% is good in healthcare)

• Net Margin: 5.0% (Note: Profitability after taxes and all expenses. Above 5% adequate; but around the industry average)

• Last 5-Year Sales Growth: 11.3% (Note: Compound annual growth rate of sales. Growth above 10% is considered strong)

• Last 5-Year EPS Growth: 6.5% (Note: Earnings per share growth. Moderate; above 10% would be much stronger)

• ROE (Return on Equity): 21.4% (Note: A high return on equity is positive for investors; above 15% is very good)

• ROIC (Return on Invested Capital): 10.5% (Note: Effective use of invested capital. Above 10% is considered healthy)

• Long-term Debt/Equity: 0.8 (Note: Debt-to-equity ratio below 1 is considered safe)

• Debt/Cash Ratio: Net debt $50.6B, cash $28.6B → 1.77x (Note: A value below 2 indicates a manageable debt burden)

• PEG Ratio: -0.3 (Note: A negative value indicates weak future growth expectations. Generally, a value below 1 is considered cheap, but growth is declining here)

• P/E Ratio: 13.2 | Forward P/E: 18.7 (Note: A value below 20 is cheap based on past profitability, but forward-looking forecasts are deteriorating)

• Forward Price/FCF: 15.3 (Note: A value below 20 is considered positive for investors)

• Free Cash Flow Margin: 6.0% (Note: Above 5% is satisfactory. FCF growth is strong, averaging 13.17% annually)

• Share Dilution: The number of shares has decreased through buybacks in recent years; Positive for Investors

4) Note to Investors

As one of the largest health insurance and service providers in the United States and the world, UnitedHealth Group stands out for its diversified revenue streams and massive scale.

Strengths:

• Economic protection (MOAT) thanks to the integration of health insurance, data, and pharmacy
• Strong ROE and FCF generation
• Manageable debt ratio and stable dividend history (33 years of dividends)
• Management reforms and insider buying signals are positive

Weaknesses:

• Significant cost pressures in Medicare Advantage and Medicaid
• Sharp decline in 2025 EPS estimates ($25 → $16)
• Negative PEG, indicating weak short-term growth potential
• Operational challenges (especially on OptumHealth)

In summary: A company with solid long-term fundamentals but facing challenges in the short- to medium-term. The stock price experienced a significant decline in 2025, and operational improvements are essential for recovery.

5) Analyst Average Target Prices

Average Target Price: $312.95
Current Price: $304.01
Potential Return: +2.94%
Highest Target: $440 (+44% potential)
Lowest Target: $198 (-35% risk)

Analyst Commentary: 18 out of 22 analysts recommend "BUY," 2 recommend "HOLD," and 2 recommend "SELL."
Source: TipRanks (August 2025)

6) Summary

UnitedHealth Group (USDUNH) is an attractive asset for long-term investors thanks to its diversified industry, scale advantage, and stable cash flow. However, unexpected medical cost increases in 2025 have significantly impacted the company's outlook. As profitability declines, management is focusing on restructuring and reforms. While large-scale insider buying and sustained earnings indicate potential for recovery, short-term risks are key factors investors should consider. It's a combination of strong long-term and weak short-term signals.

Conclusion: An Opportunity That Can't Be Ignored. In short, UnitedHealth today:

• Limited share supply (under 100 million shares),
• Concentration of smart money and insider buying,
• Cheap valuation and strong dividend policy,
• Aggressive buyback program,
• Return of experienced leader

combined with factors such as this, could potentially lead to a much faster recovery. While short-term volatility may persist, in the long run, this outlook could transform UnitedHealth not only into a healthcare giant but also one of Wall Street's surprise stories.

The information, comments and recommendations contained herein are not within the scope of investment consultancy. Investment consultancy services are provided within the framework of the investment consultancy agreement to be signed between brokerage firms, portfolio management companies, banks that do not accept deposits and customers. The comments in this article are only my personal comments and these comments may not be appropriate for your financial situation and risk return. For this reason, investments should not be made based on the information and comments in my articles.